![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Week 144 Renal Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF (STB)
from Two Phase 3 Randomized Controlled Trials
|
|
|
Reported by Jules Levin
20th International AIDS Conference, July 20-25, 2014, Melbourne
C Cohen1, F Post2, J Winston3, B Hendry2, B Gazzard4, P Girard5, G Faetkenheur6, A Antinori7, M Fisher8, C Tran-Muchowski9, H Liu9, D Piontkowsky9, M Rhee9, J Szwarcberg9
1Community Research Initiative, Boston, MA, USA; 2KingÕs college London School of Medicine, UK; 3Mount Sinai School of Medicine, New York, NY, USA; 4Chelsea and Westminister Hospital, London, UK; 5 5H™pital Saint-Antoine, Paris, France Universitˇ Pierre et Marie Curie, Paris, France; 6University Hospital of Cologne, Cologne, Germany; 7Istituto Nazionale per le Malattie Infettive, Rome Italy; 8Brighton and Sussex Medical School, Brighton, UK; 9Gilead Sciences, Foster City, CA, USA
![IAC1.gif](../images/072814/072814-5/IAC1.gif)
![IAC2.gif](../images/072814/072814-5/IAC2.gif)
![IAC3.gif](../images/072814/072814-5/IAC3.gif)
![IAC4.gif](../images/072814/072814-5/IAC4.gif)
![IAC5.gif](../images/072814/072814-5/IAC5.gif)
![IAC6.gif](../images/072814/072814-5/IAC6.gif)
![IAC7.gif](../images/072814/072814-5/IAC7.gif)
![IAC8.gif](../images/072814/072814-5/IAC8.gif)
![IAC9.gif](../images/072814/072814-5/IAC9.gif)
![IAC10.gif](../images/072814/072814-5/IAC10.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|